Hans Grönlund
Founder
NEOGAP Therapeutics AB
The startup develops personalized cancer immunotherapy that identifies optimal neoantigens to target and activate T-lymphocytes for the precise elimination of cancer cells. This approach aims to enhance patient recovery by tailoring treatments to individual tumor profiles, improving efficacy in cancer management.
- Artificial Intelligence
- Biotechnology
- Healthcare Technology
- Software Only
Updated 21 months ago
Funding
Raised to date
$11.3MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Many cancer patients do not respond to first-line treatments like chemotherapy, radiation therapy, and surgery, and these treatments can cause severe side effects that impact the patient’s quality of life. Solid cancers, in particular colorectal cancer, are often considered uncurable.
Solution
NEOGAP Therapeutics is developing personalized cancer immunotherapy for solid tumors. The approach uses the patient's own immune cells, trained to target and eliminate cancer cells, providing a tailor-made treatment for each patient. NEOGAP's approach identifies optimal neoantigens to target using a machine learning-based software platform called PIOR®. The company then uses its patented EpiTCer® technology to train the patient’s T cells to target the identified neoantigens by designing and producing neoantigens and attaching them to magnetic beads.
Target Audience
The primary target audience includes patients with solid tumors, particularly colorectal cancer, who have not responded to traditional treatments, as well as oncologists and researchers in the field of immuno-oncology.
Features
- PIOR®: A software platform that uses machine learning-based algorithms to select optimal neoantigens in a tumor.
- EpiTCer®: A method of training the patient’s T cells to target the identified neoantigens.
- pTTL cell therapy: Targets neoantigens, generating T cells using immune cells from cancer patients as starting material.
- Development of neoantigens, which are key components in Neogap’s personalised cancer therapies.